公开(公告)号：US09998198B2

公开(公告)日：2018-06-12

申请号：US15346747

申请日：2016-11-09

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Avishay Gal-Yam ,  Barak Zackay ,  Eran Ofek

IPC: H04B1/00 ,  H04B7/08 ,  H04B17/20

CPC classification number: H04B7/0851 ,  H04B17/20 ,  H04B17/318 ,  H04B17/3912

Abstract: A method for detecting a dispersed pulse in a received signal that has been dispersed by a dispersive medium includes obtaining an input array of cells, each indicating an intensity of a frequency component of the signal at a representative time. A fast dispersion measure transform (FDMT) is applied to concurrently sum the cells of the input array that lie along different dispersion curves, each curve defined by a known non-linear functional form and being uniquely characterized by a time coordinate and by a value of the dispersion measure. Application of FDMT includes initially generating a plurality of sub-arrays, each representing a frequency sub-band and iteratively combining pairs of adjacent sub-arrays in accordance with an addition rule until all of the initially generated plurality of sub-arrays are combined into an output array of the sums, in which a cell of the output array that is indicative of a transmitted pulse is identified.

公开(公告)号：US09982051B2

公开(公告)日：2018-05-29

申请号：US15821678

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/7068 ,  A61K38/00 ,  A61K38/18 ,  A61K38/16 ,  A61K38/02 ,  A61K45/06 ,  A61K31/4155 ,  A61K38/14 ,  A61K38/20 ,  A61K33/36 ,  A61K31/404 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US09982050B2

公开(公告)日：2018-05-29

申请号：US15821672

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/16 ,  A61K31/7068 ,  A61K45/06 ,  A61K38/18 ,  A61K38/14 ,  A61K38/00 ,  A61K38/20 ,  A61K33/36 ,  A61K31/404 ,  A61K31/4155 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US09982048B2

公开(公告)日：2018-05-29

申请号：US15821595

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/16 ,  A61K31/7068 ,  A61K45/06 ,  A61K38/18 ,  A61K38/14 ,  A61K38/00 ,  A61K38/20 ,  A61K33/36 ,  A61K31/404 ,  A61K31/4155 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US20180140648A1

公开(公告)日：2018-05-24

申请号：US15575827

申请日：2016-05-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran SEGAL ,  Eran ELINAV

IPC: A61K35/747 ,  A61K35/745 ,  A61P3/08

CPC classification number: A61K35/747 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K2300/00 ,  A61P3/08 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/475

Abstract: A method of improving the glucose response in glucose tolerant and intolerant subjects is provided. The method comprises providing to the subject probiotic compositions, or agents which specifically reduce bacterial species.

公开(公告)号：US20180134808A1

公开(公告)日：2018-05-17

申请号：US15865479

申请日：2018-01-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit SAGI ,  Tamar DANON ,  Netta SELA ,  Abraham SHANZER ,  Rina ARAD-YELLIN ,  Raghavendra KIKKERI

IPC: C07K16/44 ,  C07F3/06 ,  C07D233/61 ,  C07K16/40

CPC classification number: C07K16/44 ,  C07D233/61 ,  C07F3/06 ,  C07K16/40 ,  C07K2317/565 ,  C07K2317/76

Abstract: An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.

公开(公告)号：US09966458B2

公开(公告)日：2018-05-08

申请号：US15178951

申请日：2016-06-10

Applicant: Westfälische Wilhelms Universität Münster ,  Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science

Inventor： Benjamin Göhler ,  Volker Hamelbeck ,  G. Friedrich Hanne ,  Helmut Zacharias ,  Ron Naaman ,  Tal Zvi Markus

IPC: H01L29/66 ,  B82Y10/00 ,  H01L51/00 ,  H01L51/05

CPC classification number: H01L29/66984 ,  B82Y10/00 ,  H01L51/0093 ,  H01L51/0595

Abstract: The present invention relates to a method and a device for providing a current of spin-polarized electrons. More particularly, the present invention is suited for use in spin electronics or detection of spin-polarized electrons.

公开(公告)号：US20180119227A1

公开(公告)日：2018-05-03

申请号：US15724309

申请日：2017-10-04

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Zvi LIVNEH ,  Tamar PAZ-ELIZUR

IPC: C12Q1/6886 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  G01N33/57423

Abstract: Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1 and OGG1 in peripheral blood cells of a subject, wherein levels of MPG above a predetermined reference value, or APE1 or OGG1, or a integrated DNA repair score below a predetermined reference value is indicative of an increased risk of developing lung cancer.

公开(公告)号：US20180117173A1

公开(公告)日：2018-05-03

申请号：US15573550

申请日：2016-05-19

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Valery KRIZHANOVSKY ,  Yossi OVADYA

IPC: A61K47/68 ,  C12N15/113 ,  C07K16/18 ,  A61P35/00 ,  A61K45/06

CPC classification number: A61K47/6843 ,  A61K45/06 ,  A61K47/6807 ,  A61K47/6849 ,  A61P35/00 ,  C07K16/18 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/3513

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

公开(公告)号：US20180071369A1

公开(公告)日：2018-03-15

申请号：US15561053

申请日：2016-03-31

Applicant: Yeda Research and Development Co. Ltd.

Inventor： David MIRELMAN ,  Aharon RABINKOV ,  Angela RUBAN ,  Ghil JONA ,  Eli HAZUM ,  Vladas BUMELIS ,  Nerijus MAKAUSKAS ,  Saule SUDZIUVIENE ,  Elena NARMONTAITE

IPC: A61K38/45 ,  C12N9/10

CPC classification number: A61K38/45 ,  C12N9/1096 ,  C12Y206/01001

Abstract: A protein preparation comprising Glutamate Oxaloacetate Transaminase 1 (GOT1) polypeptide molecules is disclosed, the GOT1 being identical in its sequence to that present in human serum. 100% of the GOT1 polypeptide molecules of the preparation have an alanine at position 1 of the GOT1 polypeptide. The GOT1 polypeptide molecules constitute at least 95% of the proteins in the preparation. Methods of generating same and uses thereof are also disclosed.